neihulizumab

Neihulizumab is a first-in-class humanized monoclonal antibody that acts as an immune checkpoint agonist by binding to CD162 (also known as P-selectin glycoprotein ligand 1 or PSGL-1) on activated T lymphocytes. This binding preferentially induces apoptosis and downregulation of late-stage activated T cells while sparing resting and early-activated T cells. By targeting pathogenic T cells involved in inflammatory conditions, neihulizumab aims to reduce T-cell-mediated immune responses and control inflammation in diseases such as ulcerative colitis, psoriatic arthritis, plaque psoriasis, and acute graft-versus-host disease. The drug is being developed primarily for treatment-refractory autoimmune diseases and has orphan drug status for graft-versus-host disease[1][2][3][5][6][8].

Other names

neihulizumab